← Back to all substances
A

glimepiride

229ms
Level 1

✓ What this shows

  • • Reported adverse events from FDA FAERS
  • • Descriptive statistics from a locked corpus
  • • Data verified with cryptographic hashes

✗ What this is NOT

  • • Not medical advice or recommendations
  • • Not proof of causality
  • • Not a complete safety profile

About this substance

Class: Sulfonylurea [EPC]

1 INDICATIONS AND USAGE Glimepiride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [see Clinical Studies (14.1) ]. Limitations of Use Glimepiride tablets should not be used for the treatment of type 1 diabetes mellitus or ...

Known as: Glimepiride
Route: ORAL
Source: OpenFDA Drug Labels · Reference only · Not medical advice
500
Events in Corpus
v20260131-01
38,966
Total in FDA
63%
Serious Reports
46
Fatal Outcomes

Seriousness

Serious
314
Non-Serious
186

Sex Distribution

Male
267
Female
224
Unknown
9

Age Distribution

0-17
3
18-40
3
41-64
166
65-84
224
85+
19
Unknown
85

Outcomes

Recovered/Resolved
327
Recovering/Resolving
132
Not Recovered/Not Resolved
254
Recovered with Sequelae
6
Fatal
46
Unknown
895

Top Reported Reactions (click to view reports)

Verification Data

Corpus Version: v20260131-01
Root Hash: ec5727564d1ed19be5b08b26d3866f446b12d3d388f5a8cd713332c6d97ad264
Stats Hash: N/A
EVE Decision ID: EVE-MED-20260402-662779
ℹThis output reports adverse events from FDA FAERS. It does not constitute medical advice.

Molecular Structure (reference)

Structural visualization for identification only.

This visualization shows the molecular structure for identification purposes only. It does not represent pharmacological effect, safety, or clinical relevance.

Loading structure...